ASTRAZENECA PLC-SPONS ADR (AZN) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:AZN • US0463531089

188.01 USD
-5.02 (-2.6%)
At close: Feb 9, 2026
188 USD
-0.01 (-0.01%)
After Hours: 2/9/2026, 5:05:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 191 industry peers in the Pharmaceuticals industry. AZN has an excellent profitability rating, but there are some minor concerns on its financial health. AZN is not valued too expensively and it also shows a decent growth rate. AZN also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year AZN was profitable.
  • In the past year AZN had a positive cash flow from operations.
  • AZN had positive earnings in each of the past 5 years.
  • In the past 5 years AZN always reported a positive cash flow from operatings.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

  • AZN has a Return On Assets of 8.21%. This is amongst the best in the industry. AZN outperforms 89.53% of its industry peers.
  • With an excellent Return On Equity value of 20.48%, AZN belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
  • AZN has a better Return On Invested Capital (14.42%) than 94.24% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.65%.
  • The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROIC 14.42%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • With an excellent Profit Margin value of 16.17%, AZN belongs to the best of the industry, outperforming 88.48% of the companies in the same industry.
  • In the last couple of years the Profit Margin of AZN has grown nicely.
  • With an excellent Operating Margin value of 24.34%, AZN belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
  • AZN's Operating Margin has improved in the last couple of years.
  • AZN has a better Gross Margin (81.90%) than 85.86% of its industry peers.
  • In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
Industry RankSector Rank
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
  • The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for AZN has been increased compared to 5 years ago.
  • The debt/assets ratio for AZN is higher compared to a year ago.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 6.24 indicates that AZN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of AZN (6.24) is better than 78.53% of its industry peers.
  • The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
  • AZN's Debt to FCF ratio of 3.41 is amongst the best of the industry. AZN outperforms 87.96% of its industry peers.
  • AZN has a Debt/Equity ratio of 0.61. This is a neutral value indicating AZN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.61, AZN is not doing good in the industry: 67.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Altman-Z 6.24
ROIC/WACC1.58
WACC9.14%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.88 indicates that AZN may have some problems paying its short term obligations.
  • AZN's Current ratio of 0.88 is on the low side compared to the rest of the industry. AZN is outperformed by 87.43% of its industry peers.
  • A Quick Ratio of 0.69 indicates that AZN may have some problems paying its short term obligations.
  • The Quick ratio of AZN (0.69) is worse than 86.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.69
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
  • The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
  • AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
  • Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%

3.2 Future

  • AZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.37% yearly.
  • Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 7.20% on average per year.
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 40.87, which means the current valuation is very expensive for AZN.
  • Based on the Price/Earnings ratio, AZN is valued a bit cheaper than 77.49% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of AZN to the average of the S&P500 Index (27.93), we can say AZN is valued slightly more expensively.
  • Based on the Price/Forward Earnings ratio of 35.35, the valuation of AZN can be described as expensive.
  • AZN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AZN is cheaper than 70.68% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AZN to the average of the S&P500 Index (27.77), we can say AZN is valued slightly more expensively.
Industry RankSector Rank
PE 40.87
Fwd PE 35.35
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AZN is valued a bit cheaper than the industry average as 79.58% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AZN indicates a somewhat cheap valuation: AZN is cheaper than 77.49% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 60.93
EV/EBITDA 30
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZN does not grow enough to justify the current Price/Earnings ratio.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • AZN's earnings are expected to grow with 12.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.82
PEG (5Y)2.2
EPS Next 2Y13.43%
EPS Next 3Y12.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • AZN has a Yearly Dividend Yield of 1.75%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.94, AZN pays a better dividend. On top of this AZN pays more dividend than 92.15% of the companies listed in the same industry.
  • AZN's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.75%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 1.40%.
  • AZN has paid a dividend for at least 10 years, which is a reliable track record.
  • AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • 52.89% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
  • The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (2/9/2026, 5:05:00 PM)

After market: 188 -0.01 (-0.01%)

188.01

-5.02 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-10
Inst Owners49.17%
Inst Owner Change0.59%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap582.94B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target202.76 (7.85%)
Short Float %0.41%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield 1.75%
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)108.28%
PT rev (3m)121.45%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-0.46%
EPS NY rev (1m)2.29%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 40.87
Fwd PE 35.35
P/S 10.03
P/FCF 60.93
P/OCF 38.5
P/B 12.7
P/tB N/A
EV/EBITDA 30
EPS(TTM)4.6
EY2.45%
EPS(NY)5.32
Fwd EY2.83%
FCF(TTM)3.09
FCFY1.64%
OCF(TTM)4.88
OCFY2.6%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)2.82
PEG (5Y)2.2
Graham Number39.14
Profitability
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROCE 17.6%
ROIC 14.42%
ROICexc 16.02%
ROICexgc 81.56%
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
FCFM 16.46%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Debt/EBITDA 1.34
Cap/Depr 84.97%
Cap/Sales 9.59%
Interest Coverage 10.83
Cash Conversion 73.11%
Profit Quality 101.79%
Current Ratio 0.88
Quick Ratio 0.69
Altman-Z 6.24
F-Score7
WACC9.14%
ROIC/WACC1.58
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%

ASTRAZENECA PLC-SPONS ADR / AZN FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.


How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for AZN stock?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 40.87 and the Price/Book (PB) ratio is 12.7.


What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 14.52% in the next year.